p16基因CT CEA联合检测对肺癌的诊断价值  

Diagnostic Value of Combination of Detecting Aberrant p16 Promoter Methylation,CT and CEA Measurements for Lung Cancer

作　　者：胡灼君[1] 刘大鹰[1] 胡宏波[2] 

机构地区：[1]柳州市柳铁中心医院呼吸内科,广西壮族自治区柳州市545007 [2]柳州市柳铁中心医院检验科,广西壮族自治区柳州市545007

出　　处：《中国肿瘤临床》2010年第24期1440-1442,1446,共4页Chinese Journal of Clinical Oncology

基　　金：广西壮族自治区科技厅基金资助(编号:0719006-2-28)~~

摘　　要：目的:探讨P16基因甲基化、CT及血清CEA联合检测对肺癌的诊断价值。方法:选择67例临床疑似肺癌的患者,同步进行p16基因的甲基化检测、CT检查、血清癌胚抗原(CEA)测定。结果:67例患者最后确诊为肺癌42例,其余25例为良性病变。p16基因甲基化检测诊断肺癌的敏感性、特异性和准确性分别为52.4%、96.0%、68.7%;CT检查为80.9%、80.0%、80.6%;CEA检测为54.8%、76.0%、62.7%。三种方法联合检测为92.9%、84.0%、89.6%。经统计学分析,三种检查联合与单独检测的敏感性相比差异有统计学意义(x^2=23.805,P=0.000),联合检测优于三种方法单独检测(x^2=15.090,P=0.000;x^2=18.607,P=0.000;x^2=44.896,P=0.000)。结论:联合p16基因甲基化、CT和CEA检查提高了在肺癌的诊断及良恶性病变鉴别中的价值。Objective： To explore the clinical diagnostic value of the combination of detecting aberrant p16 promoter methylation, CT and carcinoembryonic antigen （CEA） measurements for lung cancer. Methods： Sixty-seven cases with suspected lung cancer underwent detection of aberrant promoter methylation of p16 gene in plasma, CT and measurement of CEA in serum. Results： Qf the 67 cases with suspected lung cancer, 42 cases were diagnosed with lung cancer and the others were diagnosed with benign lung disease. The diagnostic sensitivity, specificity and accurate value in assessing lung carcinomas were 52.4%, 96.0% and 68.7% with aberrant promoter methylation of p16 gene 8 0.9%, 80.0% and 80.6% with CT5 4.8%, 76.0% and 62.7% with CEA measurements respectively and were 92.9%, 84.0% and 89.6% with combined de- tection of the three methods, respectively. Conclusion： The combination of the three methods p16 gene aberrant promoter methylation, CT and CEA measurements may be helpful in improving the diagnosis of lung cancer and is the better choice for differentiating benign pulmonary lesions from malignant ones.

关 键 词：肺肿瘤 P16基因 体层摄影术 癌胚抗原 

分 类 号：R734.2[医药卫生—肿瘤]